Chronic hepatitis B (CHB) affects over 350 million individuals worldwide and is the most common cause of liver cancer. In the United States, CHB affects at least 2 to 3 million individuals, and current therapies can control the disease but not cure it. There are over 30 new molecules being studied in CHB in preclinical to phase 2 studies, targeting specific parts of the hepatitis B virus (HBV) life cycle and the host immune response. When discussing new therapies for CHB, it is critical to understand both the various phases of CHB and the life cycle of HBV. This article will discuss both of these issues, as well as mechanisms of action of potential therapies and possible ways to combine such therapies in the various phases of CHB.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495044PMC

Publication Analysis

Top Keywords

hepatitis virus
8
life cycle
8
phases chb
8
chb
6
direct-acting antiviral
4
antiviral agents
4
agents immunomodulators
4
immunomodulators hepatitis
4
virus infection
4
infection chronic
4

Similar Publications

Objectives: Due to the severe shortage of donor corneas for transplantation in China, corneal component transplantation may expand the available donor pool. This study aims to evaluate the safety and feasibility of corneal component transplantation by examining the distribution of hepatitis B surface antigen (HBsAg) in corneas from HBsAg-seropositive donors under different storage media.

Methods: Ten corneas (from 6 donors) donated between December 2019 and March 2021 and stored at the Eye Bank of Xiangya Third Hospital, Central South University, were analyzed.

View Article and Find Full Text PDF

Objectives: While there is growing evidence that physical activity reduces the risk of hepatocellular carcinoma (HCC), the impact of occupational physical activity and sedentary behaviour remains unclear. This study aimed to investigate the associations between occupational physical activity and sedentary behaviour and HCC risk.

Design: Matched case-control study.

View Article and Find Full Text PDF

Immune memory in hepatitis E virus: a comparative study of natural infection and vaccination in a nursing home population.

J Immunol

February 2025

Department of Emergency Medicine, Second Affiliated Hospital, Department of Epidemiology and Biostatistics, School of Public Health, The Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, 310058, China.

Immune memory is crucial for preventing hepatitis E virus (HEV) infection. Our study aims to investigate immunological memory characteristics and differences between vaccination and natural HEV infection, taking into account that both can induce immune memory. We recruited 60 HEV-infected patients, 58 contingency HEV-vaccinated individuals and 4 controls from an outbreak of hepatitis E in a nursing home between June and August 2023.

View Article and Find Full Text PDF

Project HCV Connect: Using a County Surveillance Registry to Link Hepatitis C Virus-Infected Residents to Cure-Los Angeles County, April 2023 to March 2024.

J Public Health Manag Pract

March 2025

Author Affiliations: Keck School of Medicine,Department of Population and Public Health Sciences, University of Southern California, Los Angeles, California (Dr Stafylis, Ms Hernandez-Tamayo, Mr Bhardwaj, Ms Shah, Ms Becerra, Ms Bruce, Ms Saini, Ms Saremi, Mr Thomas, Ms Manansala-Tan, Mr Vij, Ms Li, Mr Sudeep, Mr Gizamba, Mr Hosseini, Ms Navarro, Ms Ufret-Rivera, Dr Gounder, and Dr Klausner); and Los Angeles County Department of Public Health, Acute Communicable Disease Control, Viral Hepatitis Unit, Los Angeles, California (Ms Jewell).

Los Angeles County has a high prevalence of chronic hepatitis C virus (HCV) infection, but resources and infrastructure to notify and increase treatment uptake among county residents are absent. Through an innovative academic-public partnership, we developed a linkage-to-cure program utilizing the Department of Public Health's HCV surveillance registry. Case workers contacted reported cases via phone, to offer education, and treatment referral.

View Article and Find Full Text PDF

Proteasomal processing of the viral replicase ORF1 facilitates HEV-induced liver fibrosis.

Proc Natl Acad Sci U S A

March 2025

Department of Hepatobiliary and Pancreatic Surgery and Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.

Chronic infections with hepatitis E virus (HEV), especially those of genotype 3 (G3), frequently lead to liver fibrosis and cirrhosis in patients. However, the causation and mechanism of liver fibrosis triggered by chronic HEV infection remain poorly understood. Here, we found that the viral multiple-domain replicase (ORF1) undergoes unique ubiquitin-proteasomal processing leading to formation of the EV-erived MAD ctivator (HDSA), a viral polypeptide lacking putative helicase and RNA polymerase domains.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!